Eczema Drug's ethnic secrets revealed in new study
NCT ID NCT05268107
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the eczema drug dupilumab works in people of different ethnic backgrounds. Researchers want to understand why Asian and African American people get eczema more often and respond differently to treatment. The study will compare 30 adults with moderate-to-severe eczema from Caucasian, Asian, and African American groups. It does not test a new treatment but aims to improve future care for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?